BR9405856A - Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório - Google Patents

Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório

Info

Publication number
BR9405856A
BR9405856A BR9405856A BR9405856A BR9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A BR 9405856 A BR9405856 A BR 9405856A
Authority
BR
Brazil
Prior art keywords
contents
actin
pathological
respiratory tract
viscosity
Prior art date
Application number
BR9405856A
Other languages
English (en)
Inventor
Thomas P Stossel
Stuert E Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of BR9405856A publication Critical patent/BR9405856A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716Muscle proteins, e.g. myosin, actin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53Ligases (6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/12Mucolytics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9405856A 1993-04-02 1994-04-04 Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório BR9405856A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
PCT/US1994/003667 WO1994022465A1 (en) 1993-04-02 1994-04-04 Method for reducing the viscosity of pathological mucoid airway contents in the respiratoy tract

Publications (1)

Publication Number Publication Date
BR9405856A true BR9405856A (pt) 1996-03-05

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9405856A BR9405856A (pt) 1993-04-02 1994-04-04 Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório

Country Status (17)

Country Link
US (2) US5464817A (pt)
EP (1) EP0692970B1 (pt)
JP (2) JPH08510998A (pt)
KR (1) KR100308679B1 (pt)
CN (1) CN1107521C (pt)
AT (1) ATE182790T1 (pt)
AU (1) AU695033B2 (pt)
BR (1) BR9405856A (pt)
CA (1) CA2159205A1 (pt)
DE (1) DE69419907T2 (pt)
DK (1) DK0692970T3 (pt)
ES (1) ES2135576T3 (pt)
GB (1) GB2293102B (pt)
GR (1) GR3031753T3 (pt)
NO (1) NO953862D0 (pt)
SG (1) SG49574A1 (pt)
WO (1) WO1994022465A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
PT811068E (pt) * 1995-02-24 2003-04-30 Genentech Inc Variantes da adnase i humana
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
WO1998024465A1 (en) 1996-12-04 1998-06-11 The Victoria University Of Manchester Wound healing and treatment of fibrosis
EP1249244A1 (en) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
CN1329078C (zh) * 2001-12-28 2007-08-01 阿斯比奥制药株式会社 造血干细胞和/或造血前体细胞的增殖和/或分化促进剂
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
WO2005112970A2 (en) * 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
US20060030539A1 (en) * 2004-08-06 2006-02-09 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
EP1880733A4 (en) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
PL2001496T3 (pl) 2006-03-15 2017-10-31 Brigham & Womens Hospital Inc Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
CN101460843B (zh) * 2006-03-15 2018-06-22 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗多发性硬化和诊断神经疾病的用途
PL2095825T3 (pl) * 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
WO2008101084A2 (en) 2007-02-15 2008-08-21 National Jewish Medical And Research Center Methods and compositions for the disruption of biofilms
CA3080273C (en) * 2008-01-25 2022-11-22 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
WO2013114371A1 (en) 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
WO1991015770A1 (en) * 1990-04-11 1991-10-17 The General Hospital Corporation Therapeutic uses of actin-binding compounds
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
EP0692970A1 (en) 1996-01-24
GB2293102B (en) 1996-10-09
GB2293102A (en) 1996-03-20
GR3031753T3 (en) 2000-02-29
ES2135576T3 (es) 1999-11-01
SG49574A1 (en) 1998-06-15
JP2001302537A (ja) 2001-10-31
ATE182790T1 (de) 1999-08-15
KR100308679B1 (ko) 2001-11-30
JPH08510998A (ja) 1996-11-19
AU695033B2 (en) 1998-08-06
NO953862L (no) 1995-09-29
WO1994022465A1 (en) 1994-10-13
DE69419907T2 (de) 1999-12-09
AU6625094A (en) 1994-10-24
CA2159205A1 (en) 1994-10-13
CN1122108A (zh) 1996-05-08
DK0692970T3 (da) 1999-12-06
CN1107521C (zh) 2003-05-07
US5464817A (en) 1995-11-07
DE69419907D1 (de) 1999-09-09
NO953862D0 (no) 1995-09-29
EP0692970B1 (en) 1999-08-04
GB9520020D0 (en) 1995-12-06
US5656589A (en) 1997-08-12

Similar Documents

Publication Publication Date Title
BR9405856A (pt) Processo para redução de viscosidade de conteúdo de vias aéreas mocóides patológicos no trato respiratório
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
BR9713521A (pt)
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
CY1112330T1 (el) Πρωτεϊνες συνδεσης gag
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
FI943028A (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
ATE338130T1 (de) Cdna für humane methyllentetrahydrofolatreduktase
DE69516416D1 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
NO885013D0 (no) FremgangsmŸte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppnŸdd ved fremgangsmŸten.
WO2004020668A3 (en) Method for treating synovial sarcoma
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
BR9808729A (pt) Processo para a preparação de um anti-oxidante
PT782630E (pt) Gene da doenca poliquistica do rim
IL129910A0 (en) Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis
NZ334762A (en) Human DNase I variants having binding affinity to actin
BR9909180A (pt) Utilização de pelo menos um fragmento de uma proteìna de membrana e processo de prepração de uma proteìna ou um de seus fragmentos por via recombinante
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
ES2063161T3 (es) Proteinas modificadas.
KR950003312A (ko) 연골세포 단백질
TR200002611T2 (tr) Beta-lipotropin ve kullanımları

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/47 (2006.01), A61K 38/17 (2006.0